Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Clinical trial NCT02785952 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02785952
- Sponsor
- SWOG Cancer Research Network
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-29
- Primary completion
- 2019-12-19
- Enrollment
- 275
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.